Verified discoveries, trials, and approvals for this cancer type. Every story separates evidence strength, regulatory status, and guideline position.
An investigational alpha-lactalbumin-targeted vaccine, developed by Anixa Biosciences with Cleveland Clinic, was reported to be safe and to induce a protocol-defined immune response in 74% of participants across all three…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed
In the randomized, phase 3 ASCENT-07 trial, sacituzumab govitecan did NOT improve progression-free survival compared with standard-of-care chemotherapy as a first chemotherapy option for hormone-receptor-positive, HER2-negative advanced breast cancer --…
Primary source cited
Last reviewed
In a large randomized trial (105,934 participants), AI-supported mammography reading achieved a lower interval-cancer rate than standard double reading (1.55 vs. 1.76 per 1,000, meeting noninferiority) with higher sensitivity (80.5%…
Primary source cited
Last reviewed
A specific expanded FDA approval exists for trastuzumab deruxtecan in a defined HR-positive, HER2-low/ultralow metastatic breast cancer population after endocrine therapy, based on a significant progression-free-survival benefit in DESTINY-Breast06.
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled INAVO120 trial, adding inavolisib to palbociclib and fulvestrant significantly delayed disease progression compared with palbociclib and fulvestrant alone, in a PIK3CA-mutated, endocrine-resistant, first-line metastatic breast…
Primary source cited
Last reviewed
An investigational alpha-lactalbumin-targeted vaccine, developed by Anixa Biosciences with Cleveland Clinic, was reported to be safe and to induce a protocol-defined immune response in 74% of participants across all three…
Primary source cited
Last reviewed
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed
In a large randomized trial (105,934 participants), AI-supported mammography reading achieved a lower interval-cancer rate than standard double reading (1.55 vs. 1.76 per 1,000, meeting noninferiority) with higher sensitivity (80.5%…
Primary source cited
Last reviewed
A specific expanded FDA approval exists for trastuzumab deruxtecan in a defined HR-positive, HER2-low/ultralow metastatic breast cancer population after endocrine therapy, based on a significant progression-free-survival benefit in DESTINY-Breast06.
Primary source cited
Last reviewed
Important: Eligibility and enrollment are not guaranteed, and listing here is not a treatment recommendation. Talk to your care team.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
Phase 1 trial registry (investigational alpha-lactalbumin breast-cancer vaccine). NCT04674306.
Eligibility varies — review trial criteria.
This record has no structured cancer-type scope on file yet — editorial review recommended before treating it as applicable to a specific cancer type.
ASCENT-07 trial registry. NCT05840211.
Eligibility varies — review trial criteria.
Regulatory approval is separate from evidence certainty and from guideline position. Approval applies only to the exact indication stated in each jurisdiction record.
OlympiA trial primary results: adjuvant olaparib in BRCA1/2-mutated breast cancer (NEJM). DOI 10.1056/NEJMoa2105215, PMID 34081848.
Applies to the exact indication stated.
FDA-approved indication expansion; DESTINY-Breast06 (NEJM). DOI 10.1056/NEJMoa2407086, PMID 39282896.
Applies to the exact indication stated.
INAVO120 trial primary progression-free-survival results: inavolisib-based therapy in PIK3CA-mutated advanced breast cancer (NEJM). DOI 10.1056/NEJMoa2404625.
Applies to the exact indication stated.
In the randomized, double-blind, placebo-controlled OlympiA trial, one year of adjuvant olaparib significantly improved invasive disease-free survival (primary publication) and, in a later analysis, significantly improved overall survival as well…
Primary source cited
Last reviewed
CancerDiscoveries summarizes verified records in its database. Absence of a listing here does not establish that a treatment lacks regulatory authorization or access.